Daniel Passeri - Dec 16, 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol: CUE
Transactions as of: Dec 16, 2024
Transactions value $: $30,900
Form type: 4
Date filed: 12/18/2024, 04:00 PM
Previous filing: Mar 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Purchase	$30.9K	+30K	+22.29%	$1.03	165K	Dec 16, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.97 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.97 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided.